109 related articles for article (PubMed ID: 9684994)
1. Juvenile arthritis, HLA-A2 and binding of DEK oncogene-peptides.
Forero L; Zwirner NW; Fink CW; Fernández-Viña MA; Stastny P
Hum Immunol; 1998 Jul; 59(7):443-50. PubMed ID: 9684994
[TBL] [Abstract][Full Text] [Related]
2. DEK in the synovium of patients with juvenile idiopathic arthritis: characterization of DEK antibodies and posttranslational modification of the DEK autoantigen.
Mor-Vaknin N; Kappes F; Dick AE; Legendre M; Damoc C; Teitz-Tennenbaum S; Kwok R; Ferrando-May E; Adams BS; Markovitz DM
Arthritis Rheum; 2011 Feb; 63(2):556-67. PubMed ID: 21280010
[TBL] [Abstract][Full Text] [Related]
3. Selection of peptides that bind to the HLA-A2.1 molecule by molecular modelling.
Lim JS; Kim S; Lee HG; Lee KY; Kwon TJ; Kim K
Mol Immunol; 1996 Feb; 33(2):221-30. PubMed ID: 8649443
[TBL] [Abstract][Full Text] [Related]
4. DEK, an autoantigen involved in a chromosomal translocation in acute myelogenous leukemia, binds to the HIV-2 enhancer.
Fu GK; Grosveld G; Markovitz DM
Proc Natl Acad Sci U S A; 1997 Mar; 94(5):1811-5. PubMed ID: 9050861
[TBL] [Abstract][Full Text] [Related]
5. Antibodies to the 45 kDa DEK nuclear antigen in pauciarticular onset juvenile rheumatoid arthritis and iridocyclitis: selective association with MHC gene.
Murray KJ; Szer W; Grom AA; Donnelly P; Levinson JE; Giannini EH; Glass DN; Szer IS
J Rheumatol; 1997 Mar; 24(3):560-7. PubMed ID: 9058666
[TBL] [Abstract][Full Text] [Related]
6. The DEK nuclear autoantigen is a secreted chemotactic factor.
Mor-Vaknin N; Punturieri A; Sitwala K; Faulkner N; Legendre M; Khodadoust MS; Kappes F; Ruth JH; Koch A; Glass D; Petruzzelli L; Adams BS; Markovitz DM
Mol Cell Biol; 2006 Dec; 26(24):9484-96. PubMed ID: 17030615
[TBL] [Abstract][Full Text] [Related]
7. High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti-Tumor Necrosis Factor Therapy.
Mor-Vaknin N; Rivas M; Legendre M; Mohan S; Yuanfan Y; Mau T; Johnson A; Huang B; Zhao L; Kimura Y; Spalding SJ; Morris PW; Gottlieb BS; Onel K; Olson JC; Edelheit BS; Shishov M; Jung LK; Cassidy EA; Prahalad S; Passo MH; Beukelman T; Mehta J; Giannini EH; Adams BS; Lovell DJ; Markovitz DM
Arthritis Rheumatol; 2018 Apr; 70(4):594-605. PubMed ID: 29287303
[TBL] [Abstract][Full Text] [Related]
8. DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress.
Kappes F; Fahrer J; Khodadoust MS; Tabbert A; Strasser C; Mor-Vaknin N; Moreno-Villanueva M; Bürkle A; Markovitz DM; Ferrando-May E
Mol Cell Biol; 2008 May; 28(10):3245-57. PubMed ID: 18332104
[TBL] [Abstract][Full Text] [Related]
9. The putative oncoprotein DEK, part of a chimera protein associated with acute myeloid leukaemia, is an autoantigen in juvenile rheumatoid arthritis.
Sierakowska H; Williams KR; Szer IS; Szer W
Clin Exp Immunol; 1993 Dec; 94(3):435-9. PubMed ID: 8252804
[TBL] [Abstract][Full Text] [Related]
10. Identification and design of p53-derived HLA-A2-binding peptides with increased CTL immunogenicity.
Petersen TR; Buus S; Brunak S; Nissen MH; Sherman LA; Claesson MH
Scand J Immunol; 2001 Apr; 53(4):357-64. PubMed ID: 11285115
[TBL] [Abstract][Full Text] [Related]
11. DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis.
Mor-Vaknin N; Saha A; Legendre M; Carmona-Rivera C; Amin MA; Rabquer BJ; Gonzales-Hernandez MJ; Jorns J; Mohan S; Yalavarthi S; Pai DA; Angevine K; Almburg SJ; Knight JS; Adams BS; Koch AE; Fox DA; Engelke DR; Kaplan MJ; Markovitz DM
Nat Commun; 2017 Feb; 8():14252. PubMed ID: 28165452
[TBL] [Abstract][Full Text] [Related]
12. Autoantibodies to DEK oncoprotein in systemic lupus erythematosus (SLE).
Wichmann I; Respaldiza N; Garcia-Lozano JR; Montes M; Sanchez-Roman J; Nuñez-Roldan A
Clin Exp Immunol; 2000 Mar; 119(3):530-2. PubMed ID: 10691927
[TBL] [Abstract][Full Text] [Related]
13. DEK binding to class II MHC Y-box sequences is gene- and allele-specific.
Adams BS; Cha HC; Cleary J; Haiying T; Wang H; Sitwala K; Markovitz DM
Arthritis Res Ther; 2003; 5(4):R226-33. PubMed ID: 12823858
[TBL] [Abstract][Full Text] [Related]
14. MHC-peptide binding: dimers of cysteine-containing nonapeptides bind with high affinity to HLA-A2.1 class I molecules.
Di Modugno F; Mammi C; Rosanò L; Rubiu O; Nisticò P; Chersi A
J Immunother; 1997 Nov; 20(6):431-6. PubMed ID: 9409448
[TBL] [Abstract][Full Text] [Related]
15. Identification of HIV protein-derived cytotoxic T lymphocyte (CTL) epitopes for their possible use as synthetic vaccine.
Brander C; Pichler WJ; Corradin G
Clin Exp Immunol; 1995 Jul; 101(1):107-13. PubMed ID: 7621579
[TBL] [Abstract][Full Text] [Related]
16. Naturally processed peptides longer than nine amino acid residues bind to the class I MHC molecule HLA-A2.1 with high affinity and in different conformations.
Chen Y; Sidney J; Southwood S; Cox AL; Sakaguchi K; Henderson RA; Appella E; Hunt DF; Sette A; Engelhard VH
J Immunol; 1994 Mar; 152(6):2874-81. PubMed ID: 8144888
[TBL] [Abstract][Full Text] [Related]
17. Peptide-dependent expression of HLA-B7 on antigen processing-deficient T2 cells.
Smith KD; Lutz CT
J Immunol; 1996 May; 156(10):3755-64. PubMed ID: 8621911
[TBL] [Abstract][Full Text] [Related]
18. Peptide binding to MHC class I is determined by individual pockets in the binding groove.
Johansen TE; McCullough K; Catipovic B; Su XM; Amzel M; Schneck JP
Scand J Immunol; 1997 Aug; 46(2):137-46. PubMed ID: 9583994
[TBL] [Abstract][Full Text] [Related]
19. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes.
Nijman HW; Houbiers JG; Vierboom MP; van der Burg SH; Drijfhout JW; D'Amaro J; Kenemans P; Melief CJ; Kast WM
Eur J Immunol; 1993 Jun; 23(6):1215-9. PubMed ID: 7684681
[TBL] [Abstract][Full Text] [Related]
20. A novel autoantibody to the putative oncoprotein DEK in pauciarticular onset juvenile rheumatoid arthritis.
Szer IS; Sierakowska H; Szer W
J Rheumatol; 1994 Nov; 21(11):2136-42. PubMed ID: 7869324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
